Home > Back to Publisher > Report Information

Cancer Market Trends 2006 - 2010

Urch Publishing
December 1, 2006
111 Pages - SKU: URC1391981

Abstract Table of Contents Related Reports

The global cancer market has just seen a period of rapid growth. Between 2003 and 2005, global sales for cancer treating drugs increased by 40% and now account for more than eight percent of total global pharmaceutical sales. Although growth rates for this market will slow due to generic competition the market is predicted to expand to $85.3 billion by 2010 equivalent to CAGR of 11.1%

Cancer Market Trends, 2006-2010 - Key market forecasts and growth opportunities provides a superb trend analysis of the growing cancer market.

This comprehensive report delivers market forecasts and overviews to help inform you in your pharmaceutical business decision-making.

Key findings from the report include:

The worldwide incidence of new cancer patients is forecast to increase from 4.2 million cases in the major cancer markets in 2005 to 4.6 million in 2010.
The cancer having the greatest impact on the population in the leading pharmaceutical markets is cancer of the trachea, bronchus and lung.
Global cancer market growth of 16.5% in 2005 was primarily driven by growth of 41.2% in innovative sales.
The worldwide cancer market is dominated by the selected adjuncts drug class with a market share of 38.3%, followed chemotherapeutics, innovatives and then hormonals.
Five of the top 10 leading cancer products in 2005 were selected adjuncts (Eprex/ Procrit, Aranesp, Epogen, Neulasta and NeoRecormon/ Epogin), two were innovatives (Rituxan/ MabThera and Gleevec/ Glivec), two were chemotherapeutics (Taxotere and Eloxatin) and one was a hormonal (Lupron).
14 pharmaceutical companies were identified as having generated cancer sales in excess of US$1 billion in 2005.

This report provides key information needed in your business including:

Sales forecast for top ten companies providing cancer treatment medicines.
Analysis of leading cancer products likely to loose patent protection in the next ten years.
Sales forecasts to 2010 for the top ten cancer medicines and forecasts by drug class.
Overview of disease incidence, areas of growth and breakdown of disease burden and mortality.
Breakdown of the major market trends and business opportunities

Use This Report To:

Benchmark your company’s portfolio against market trends and forecasts to plan better for greater profitability.
Spot areas of pharmaceutical market growth and good opportunities for delivering successful sales growth
Support your internal planning processes by using an external perspective founded on detailed analysis and transparent market forecasts.

The 111 page publication contains 49 Figures and 43 Tables to help you make sense of the wealth of data. This report will be of particular use to those involved in:

corporate planning,
sales and marketing,
portfolio management, and,
market forecasting.

The report is divided into five key sections. Chapters 2-5 present historical trends for key disease markets, key drug classes, key products and key companies. The final report chapter outlines future cancer market trends and major growth opportunities. The data and analysis contained within the report are comprehensive, consistent and up-to-date and thus provide a single-point of reference for understanding cancer market trends.

Summary: Introduction; Key disease markets; Key drug classes; Key products; Key companies; Key trends and opportunities
Chapter 1 Introduction: Global cancer market; Report overview
Chapter 2 Key disease markets Key cancer markets: Cancer epidemiology; Cancer treatment-related disorders
Chapter 3 Key drug classes: Key drug classifications
Chapter 4 Key products: Leading products; Top 10 leading cancer drugs
Chapter 5 Key companies: Major cancer players; Leading companies
Chapter 6 Key trends and opportunities: Key disease market forecasts; Key drug class forecasts; Key product forecasts; Key company forecasts
Appendix: Proprietary data sources; Top 46 cancer products; Top 14 pharmaceutical companies by cancer sales
Figures: Figure 1: Global cancer market, 2003-2005; Figure 2: Report structure; Figure 3: Disease burden in seven major pharmaceutical markets, 2005; Figure 4: New cancer cases in the US, 2006; Figure 5: Cancer deaths in the US, 2006; Figure 6: Cancer epidemiology in seven major markets, 2005; Figure 7: Prostate cancer epidemiology in seven major markets, 2005; Figure 8: Breast cancer epidemiology in seven major markets, 2005; Figure 9: Lung and bronchus cancer epidemiology in seven major markets, 2005; Figure 10: Colorectal cancer epidemiology in seven major markets, 2005; Figure 11: Uterine corpus/ endometrium (uterus) cancer epidemiology in seven major markets, 2005; Figure 12: Urinary bladder cancer epidemiology in seven major markets, 2005; Figure 13: Non-Hodgkin’s lymphoma epidemiology in seven major markets, 2005; Figure 14: Melanoma epidemiology in seven major markets, 2005; Figure 15: Kidney and renal pelvis cancer epidemiology in seven major markets, 2005; Figure 16: Leukemia epidemiology in seven major markets, 2005; Figure 17: Global cancer market by drug class, 2005; Figure 18: Global cancer market by drug class, 2003-2005; Figure 19: Global cancer market trends by drug class, 2004-2005; Figure 20: Hormonals market, 2003-2005; Figure 21: Leading hormonal drugs by approval date, 1977-2005; Figure 22: Chemotherapeutics market, 2003-2005; Figure 23: Leading chemotherapeutic drugs by approval date, 1989-2005; Figure 24: Innovatives market, 2003-2005; Figure 25: Leading innovative drugs by approval date, 1983-2005; Figure 26: Selected adjuncts market, 2003-2005; Figure 27: Leading selected adjunct drugs by approval date, 1988-2005; Figure 28: Cancer blockbuster trends, 2004-2005; Figure 29: Top 10 cancer products by global sales, 2005; Figure 30: Top 10 companies by global cancer sales, 2005; Figure 31: Top 10 companies by global cancer market share, 2005; Figure 32: Top 10 companies by global cancer sales, 2004-2005; Figure 33: Cancer incidence forecasts by geographic market, 2005-2010; Figure 34: Cancer incidence forecasts by disease market, 2005-2010; Figure 35: Global cancer market forecast, 2003-2010; Figure 36: Global cancer market forecasts by drug class, 2003-2010; Figure 37: Top 10 cancer drugs by forecast sales, 2010; Figure 38: Rituxan/ MabThera (rituximab) forecast sales, 2003-2010; Figure 39: Eprex/ Procrit (epoetin alfa) forecast sales, 2003-2010; Figure 40: Aranesp (darbepoetin alfa) forecast sales, 2003-2010; Figure 41: Epogen (epoetin alfa) forecast sales, 2003-2010; Figure 42: Neulasta (pegfilgrastim) forecast sales, 2003-2010; Figure 43: Gleevec/ Glivec (imatinib mesylate) forecast sales, 2003-2010; Figure 44: Taxotere (docetaxel) forecast sales, 2003-2010; Figure 45: Lupron (leuprolide acetate) forecast sales, 2003-2010; Figure 46: Eloxatin (oxaliplatin) forecast sales, 2003-2010; Figure 47: NeoRecormon/ Epogin (epoetin beta) forecast sales, 2003-2010; Figure 48: Forecast patent expiries by 2005 global sales, 2006-2015; Figure 49: Top ten companies by cancer sales trends, 2005-2010
Tables: Table 1: Global cancer market trends by drug class, 2003-2005; Table 2: Leading hormonal drugs, 2005; Table 3: Hormonals market trends, 2003-2005; Table 4: Leading chemotherapeutic drugs, 2005; Table 5: Chemotherapeutics market trends, 2003-2005; Table 6: Leading innovative drugs, 2005; Table 7: Innovatives market trends, 2003-2005; Table 8: Leading selected adjunct drugs, 2005; Table 9: Selected adjuncts market trends, 2003-2005; Table 10: Top 20 cancer products by global sales, 2003-2005; Table 11: Rituxan/ MabThera (rituximab) profile, 2005; Table 12: Eprex/ Procrit (epoetin alfa) profile, 2005; Table 13: Aranesp (darbepoetin) profile, 2005; Table 14: Epogen (epoetin alfa) profile, 2005; Table 15: Neulasta (pegfilgrastim) profile, 2005; Table 16: Gleevec/ Glivec (imatinib mesylate) profile, 2005; Table 17: Taxotere (docetaxel) profile, 2005; Table 18: Lupron (leuprolide) profile, 2005; Table 19: Eloxatin (oxaliplatin) profile, 2005; Table 20: NeoRecormon/ Epogin (epoetin beta) profile, 2005; Table 21: Top 10 companies by global cancer sales, 2003-2005; Table 22: Amgen profile, 2005; Table 23: Amgen cancer pipeline, 2005; Table 24: Novartis profile, 2005; Table 25: Novartis cancer pipeline, 2005; Table 26: Roche profile, 2005; Table 27: Roche cancer pipeline, 2005; Table 28: Sanofi-Aventis profile, 2005; Table 29: Sanofi-Aventis cancer pipeline, 2005; Table 30: Genentech profile, 2005; Table 31: Genentech cancer pipeline, 2005; Table 32: AstraZeneca profile, 2005; Table 33: AstraZeneca cancer pipeline, 2005; Table 34: Johnson & Johnson profile, 2005; Table 35: Johnson & Johnson cancer pipeline, 2005; Table 36: Pfizer profile, 2005; Table 37: Pfizer cancer pipeline, 2005; Table 38: GlaxoSmithKline profile, 2005; Table 39: GlaxoSmithKline cancer pipeline, 2005; Table 40: Eli Lilly profile, 2005; Table 41: Eli Lilly cancer pipeline, 2005; Table 42: Global cancer market forecasts by drug class, 2003-2010; Table 43: Top 10 cancer drugs forecasts, 2003-2010; Table 44: Top 10 companies by cancer sales forecasts, 2005-2010; Table 45: Top 46 cancer products by global pharmaceutical sales, 2003-2005; Table 46: Top 14 companies by global cancer sales, 2003-2005

Cancer Market Trends 2006 - 2010

Share this report

Other tasks

Research Assistance

Related Markets

Oncology/Hematology Reports

Free Alert Me service